NASA’s SPHEREx space telescope has settled into low-Earth orbit, where it is transmitting data back home and providing a public wellspring of space data for both professional and citizen scientists.
First launched in March of this year, SPHEREx (the Spectro-Photometer for the History of the Universe, Epoch of Reionization, and Ices Explorer) is currently creating all-sky maps of the universe as its primary mission, with secondary goals to support other space observation platforms. While not the first all-sky mission, SPHEREx improves upon previous attempts by boasting 102 infrared wavelength observations, compared to the earlier WISE mission’s four wavelengths.
As astronomers study increasingly distant parts of the universe, spectroscopy has become a crucial tool for understanding the cosmos. This allows researchers to analyze infrared wavelength data from distant celestial bodies and identify the molecules present within them. SPHEREx scientists will utilize this technique to search for essential elements for life, such as water ice and organic molecules, throughout the Milky Way galaxy.
The telescope’s 102 wavelengths will provide precise data for the ongoing search, and the SPHEREx mission will also study universal expansion by measuring the distant light emissions from all galaxies over time.
“Because we’re looking at everything in the whole sky, almost every area of astronomy can be addressed by SPHEREx data,” said Rachel Akeson, the lead for the SPHEREx Science Data Center at IPAC. IPAC is a science and data center for astrophysics and planetary science at Caltech in Pasadena, California.
SPHEREx’s mission is currently scheduled to run for two years, during which it will complete two all-sky surveys annually, resulting in a total of four maps. Halfway through the mission, the SPHEREx team is planning to release a 102-wavelength sky map at the one-year mark.
SPHEREx is part of NASA’s overall commitment to transparency and data sharing. The data is hosted by the IPAC Infrared Science Archive (IRSA), which also contains data from other NASA infrared and submillimeter missions, such as WISE and 2MASS. By providing public access to their data, the SPHEREx team hopes others will utilize the resource to produce many more studies than what their team can accomplish alone.
“We want enough information in those files that people can do their own research,” Akeson said.
SPHEREx’s observations are available to the public within 60 days of when the readings occurred. During that roughly two-month period, the team performs processing on the data to remove or note questionable data due to artifacts, align images with their astronomical coordinates, and account for potential defects in instrumentation.
The team is also committed to being transparent about how the data is processed, publishing the procedures used in tandem with the data releases.
“SPHEREx is part of the entire legacy of NASA space surveys,” said IRSA Science Lead Vandana Desai. “People are going to use the data in all kinds of ways that we can’t imagine.”
The SPHEREx data will also provide an important supplement to other space telescope missions. Its broad scope will enable astronomers to identify interesting targets for closer observation by the James Webb Space Telescope and refine exoplanet parameters from NASA’s TESS observations.
Additionally, SPHEREx can be directed towards searching for dark matter and energy, working in tandem with the European Space Agency’s Euclid mission and NASA’s forthcoming Nancy Grace Roman Space Telescope, with a targeted May 2027 launch.
“By making the data public, we enable the whole astronomy community to use SPHEREx data to work on all these other areas of science,” Akeson said.
Ryan Whalen covers science and technology for The Debrief. He holds an MA in History and a Master of Library and Information Science with a certificate in Data Science. He can be contacted at ryan@thedebrief.org, and follow him on Twitter @mdntwvlf.
Walkers has unveiled the latest iteration of its ‘No Walkers, No Game’ advertising campaign to drum up excitement in the run up to the UEFA Women’s Euros.
Ahead of the Lionesses first game on Saturday 5th July the new ad and campaign features Lauren and Leah on their search for somewhere to watch the game. They visit unsuspecting pubs and bars surprising and delighting fans and pub goers. However, one condition of them staying to watch the game is the venue must serve Walkers. It will emphasise that there is no substitute for Walkers when the football is on, keeping the brand front of mind for shoppers stocking up on snacks ahead the UEFA Women’s Euros.
The campaign was created by Sips & Bites, PepsiCo’s in house creative agency. Shot and produced by Washington Square films with Andrew Lane directing the latest spot.
The new ad will kick off a busy summer of sport for Walkers, including a host of activity around the UEFA Women’s EURO 2025. It builds on the huge popularity of the ‘No Walkers, No Game’ campaign in 2024, which included two TV ad spots featuring Thierry Henry and a series of exclusive giveaways, putting Walkers at the heart of football fans’ matchday experiences.
This photo taken on July 4, 2025 shows the rising sun in Jiamusi City, northeast China’s Heilongjiang Province. The Earth passed the aphelion on July 4, which is the time of year when the Earth is farthest from the sun, and the apparent diameter of the sun is the smallest in the year. (Photo by Zhu Zongqiang/Xinhua)
This photo taken on July 4, 2025 shows the rising sun in Qingzhou City, east China’s Shandong Province. The Earth passed the aphelion on July 4, which is the time of year when the Earth is farthest from the sun, and the apparent diameter of the sun is the smallest in the year. (Photo by Wang Jilin/Xinhua)
This photo taken on July 4, 2025 shows the rising sun in Jiamusi City, northeast China’s Heilongjiang Province. The Earth passed the aphelion on July 4, which is the time of year when the Earth is farthest from the sun, and the apparent diameter of the sun is the smallest in the year. (Photo by Qu Yubao/Xinhua)
A tourist takes photos with the rising sun at Dongji Pavilion in Fuyuan City, northeast China’s Heilongjiang Province, July 4, 2025. The Earth passed the aphelion on July 4, which is the time of year when the Earth is farthest from the sun, and the apparent diameter of the sun is the smallest in the year. (Xinhua/Zhang Tao)
This photo taken on July 4, 2025 shows the rising sun in Yichun City, northeast China’s Heilongjiang Province. The Earth passed the aphelion on July 4, which is the time of year when the Earth is farthest from the sun, and the apparent diameter of the sun is the smallest in the year. (Photo by Li Shaojun/Xinhua)
Tourists take photos of the rising sun at Dongji Pavilion in Fuyuan City, northeast China’s Heilongjiang Province, July 4, 2025. The Earth passed the aphelion on July 4, which is the time of year when the Earth is farthest from the sun, and the apparent diameter of the sun is the smallest in the year. (Xinhua/Zhang Tao)
An aerial drone photo taken on July 4, 2025 shows the rising sun at the Sanjiangkou ecological tourism area in Tongjiang City, northeast China’s Heilongjiang Province. The Earth passed the aphelion on July 4, which is the time of year when the Earth is farthest from the sun, and the apparent diameter of the sun is the smallest in the year. (Photo by Liu Wanping/Xinhua)
Chipset on circuit board for semiconductor industry, 3d rendering
What if you could have conventional large language model output with 10 times to 20 times less energy consumption?
And what if you could put a powerful LLM right on your phone?
It turns out there are new design concepts powering a new generation of AI platforms that will conserve energy and unlock all sorts of new and improved functionality, along with, importantly, capabilities for edge computing.
Edge computing occurs when the data processing and other workloads take place close to the point of origin, in other words, an endpoint, like a piece of data collection hardware, or a user’s personal device.
Another way to describe it is that edge computing starts to reverse us back away from the cloud era, where people realized that you could house data centrally. Yes, you can have these kinds of vendor services, to relieve clients of the need to handle on-premises systems, but then you have the costs of transfer, and, typically, less control. If you can simply run operations locally on a hardware device, that creates all kinds of efficiencies, including some related to energy consumption and fighting climate change.
Enter the rise of new Liquid Foundation Models, which innovate from a traditional transformer-based LLM design, to something else.
A September 2024 piece in VentureBeat by Carl Franzen covers some of the design that’s relevant here. I’ll include the usual disclaimer: I have been listed as a consultant with Liquid AI, and I know a lot of the people at the MIT CSAIL lab where this is being worked on. But don’t take my word for it; check out what Franzen has to say.
“The new LFM models already boast superior performance to other transformer-based ones of comparable size such as Meta’s Llama 3.1-8B and Microsoft’s Phi-3.5 3.8B,” he writes. “The models are engineered to be competitive not only on raw performance benchmarks but also in terms of operational efficiency, making them ideal for a variety of use cases, from enterprise-level applications specifically in the fields of financial services, biotechnology, and consumer electronics, to deployment on edge devices.”
Then there’s this interview at IIA this April with Will Knight and Ramin Hasani, of Liquid AI.
Hasani talks about how the Liquid AI teams developed models using the brain of a worm: C elegans, to be exact.
He talked about the use of these post-transformer models on devices, cars, drones, and planes, and applications to predictive finance and predictive healthcare.
LFMs, he said, can do the job of a GPT, running locally on devices.
“They can hear, and they can talk,” he said.
Since a recent project launch, Hasani said, Liquid AI has been having commercial discussions with big companies about how to apply this technology well to enterprise.
“People care about privacy, people care about secure applications of AI, and people care about low latency applications of AI,” he said. “These are the three places where enterprise does not get the value from the other kinds of AI companies that are out there.”
Talking about how an innovator should be a “scientist at heart,” Hasani went over some of the basic value propositions of having an LLM running offline.
One of the main points that came out of this particular conversation around LFMs is that if they’re running off-line on a device, you don’t need the extended infrastructure of connected systems. You don’t need a data center or cloud services, or any of that.
In essence, these systems can be low-cost, high-performance, and that’s just one aspect of how people talk about applying a “Moore’s law” concept to AI. It means systems are getting cheaper, more versatile, and easier to manage – quickly.
So keep an eye out for this kind of development as we see smarter AI emerging.
Scarlett Johansson has just recalled a painful experience from Jurassic World Rebirth.
The Hollywood actress plays the role of Zora Bennett, who leads a team on a mission to retrieve dinosaur DNA.
During an interview with People, the Black Widow actress candidly talked about her filming experience in Thailand.
Recalling the scene in which she and Jonathan Bailey were rappelling down a cliff, Johansson said, “We wore harnesses under our actual harness.”
“You have a movie harness that looks like a harness, then you have an actual harness that’s hooked up to a line, because you’re not actually abseiling, you’re on a stunt rig.”
Sharing another incident, she told the outlet, “When we first got to Thailand, we had to do a camera test of the full costume and all that stuff, and just putting all the pieces of the costume together and then standing in a mosquito-infested bush, I was like, ‘This is really happening.’”
However, the 40-year-old actress noted that the experience was insane but also rewarding.
“We all laughed a lot, and we were thrown into such extraordinary circumstances physically. Half our set would wash away, and then ten minutes later it would grow too large, and there’s no continuity to anything because the sun was moving in. It was just insane,” she added before quitting chat.
Jurassic World Rebirth was released in cinemas on July 2, 2025.
Today is Independence Day in the United States, and many Americans will be gathering to celebrate the Fourth of July holiday with friends and family. If you are headed to a backyard BBQ, we have a fun iPhone party trick to share with you.
If you have a compatible iPhone model with a LiDAR Scanner (see the list below), you can measure a person’s height in Apple’s built-in Measure app. This way, you can see how much your nieces and nephews have grown since you last saw them, or find out if your favorite uncle is as tall as he claims he is. This might sound silly (it totally is!), but many people have no idea that iPhones offer this neat little feature.
You can save and share the photo of the person with their height measurement if you prefer.
The feature requires an iPhone model with a LiDAR Scanner:
The feature is not available on any other iPhone models.
Apple’s next-generation iPhone 17 Pro and iPhone 17 Pro Max are less than three months away, and there are plenty of rumors about the devices. Apple is expected to launch the iPhone 17, iPhone 17 Air, iPhone 17 Pro, and iPhone 17 Pro Max in September this year. Below, we recap key changes rumored for the iPhone 17 Pro models:Aluminum frame: iPhone 17 Pro models are rumored to have an…
The long wait for an Apple Watch Ultra 3 appears to be nearly over, and it is rumored to feature both satellite connectivity and 5G support. Apple Watch Ultra’s existing Night Mode In his latest Power On newsletter, Bloomberg’s Mark Gurman said that the Apple Watch Ultra 3 is on track to launch this year with “significant” new features, including satellite connectivity, which would let you…
The upcoming iPhone 17 Pro and iPhone 17 Pro Max are rumored to have a slightly different MagSafe magnet layout compared to existing iPhone models, and a leaked photo has offered a closer look at the supposed new design. The leaker Majin Bu today shared a photo of alleged MagSafe magnet arrays for third-party iPhone 17 Pro cases. On existing iPhone models with MagSafe, the magnets form a…
The iPhone 17 Pro Max will feature the biggest ever battery in an iPhone, according to the Weibo leaker known as “Instant Digital.” In a new post, the leaker listed the battery capacities of the iPhone 11 Pro Max through to the iPhone 16 Pro Max, and added that the iPhone 17 Pro Max will feature a battery capacity of 5,000mAh: iPhone 11 Pro Max: 3,969mAh iPhone 12 Pro Max: 3,687mAh…
iOS 26 and iPadOS 26 add a smaller yet useful Wi-Fi feature to iPhones and iPads. As spotted by Creative Strategies analyst Max Weinbach, sign-in details for captive Wi-Fi networks are now synced across iPhones and iPads running iOS 26 and iPadOS 26. For example, while Weinbach was staying at a Hilton hotel, his iPhone prompted him to fill in Wi-Fi details from his iPad that was already…
Apple today seeded the second betas of upcoming iOS 18.6 and iPadOS 18.6 updates to public beta testers, with the betas coming just a day after Apple provided the betas to developers. Apple has also released a second beta of macOS Sequoia 15.6. Testers who have signed up for beta updates through Apple’s beta site can download iOS 18.6 and iPadOS 18.6 from the Settings app on a compatible…
Apple’s position as the dominant force in the global true wireless stereo (TWS) earbud market is expected to continue through 2025, according to Counterpoint Research. The forecast outlines a 3% year-over-year increase in global TWS unit shipments for 2025, signaling a transition from rapid growth to a more mature phase for the category. While Apple is set to remain the leading brand by…
Apple is developing a MacBook with the A18 Pro chip, according to findings in backend code uncovered by MacRumors. Subscribe to the MacRumors YouTube channel for more videos. Earlier today, Apple analyst Ming-Chi Kuo reported that Apple is planning to launch a low-cost MacBook powered by an iPhone chip. The machine is expected to feature a 13-inch display, the A18 Pro chip, and color options…
Your eyes do more than show your brain what’s happening in the world around you. They also reveal how well your brain may fare in the years ahead, including whether or not you might develop dementia.
A long‑running study of 8,623 adults has found that a subtle slowdown in detecting a faint triangle on a computer screen can hint at Alzheimer’s disease up to 12 years before diagnosis.
Lead author Eef Hogervorst of Loughborough University says the simple test “could slot into routine checkups without adding a single drop of blood.”
Participants pressed a button when they spotted a triangle drifting amid random dots. Those who later developed dementia needed roughly two extra seconds – a gap large enough to raise their future risk by 56 percent.
The task measures visual processing speed, the time the brain takes to register and respond to a stimulus. Sluggish scores predicted dementia even after researchers adjusted for age, education, and cardiovascular health.
“Visual sensitivity is related to memory performance,” noted Hogervorst. She adds that eyesight often declines quietly, leaving people unaware until memory falters.
A similar pattern appeared in an independent analysis showing that early amyloid plaques disrupt visual signals before memory centers suffer. Taken together, the findings suggest eye‑based tests could extend the warning window for preventive care.
The retina is an outgrowth of the brain, so toxic proteins can accumulate there first. Researchers now examine retinal layers for thinning, abnormal blood vessels, and microscopic deposits that mirror cerebral changes.
Damage often begins in the occipital cortex, the region that deciphers vision, before spreading to the hippocampus. That makes contrast sensitivity, color discrimination, and motion detection early casualties.
People with Alzheimer’s also struggle to ignore distractions. “These problems could increase the risk of driving accidents,” warned Thom Wilcockson, a psychologist at Loughborough University.
Eye-tracking research confirms the concern, showing that older drivers with dementia exhibit erratic saccades, longer fixations, and reduced scanning range – all linked to crash risk.
Spotting a shape on a screen sounds trivial, yet it taps fast neural circuits shared with memory. When those circuits lag, forgetting names and appointments may follow.
The Norfolk data showed the triangle test remained significant after standard memory exams were considered. In clinics, combining both could improve accuracy while saving time and cost.
Slower vision also correlates with trouble recognizing faces, a social cue often missed in early dementia. Patients skim past eyes and mouths, failing to “imprint” new acquaintances and later feeling lost in familiar rooms.
Several groups are testing whether directed eye exercises can sharpen recall. Early trials of rapid left‑right movements report modest gains, though results remain mixed.
High‑grade eye trackers once cost thousands of dollars. A California team has squeezed similar optics into a smartphone app that uses the front‑facing infrared camera to measure pupil changes.
The prototype walks users through a brief pupil dilation task, then uploads data for cloud analysis. Engineers hope the approach will let families monitor brain health between clinic visits.
Consumer wearables are also inching closer. Some virtual‑reality headsets already track gaze direction at millisecond resolution, offering another route for large‑scale screening.
Still, technology alone is not enough. Experts stress the need for clear guidelines to avoid false alarms and protect privacy.
Lifestyle counts, too. A 14‑year study of almost 2,000 older adults found those who read at least once a week cut cognitive decline odds by nearly half.
Reading, watching subtitles, or knitting forces the eyes to dart and refocus, a workout for neural networks. Longer education and regular exercise add extra cognitive reserve, buffering the toll of disease.
Optometrists recommend annual exams after people reach 60 years of age.
Reporting new glare, color shifts, or slowed adaptation can nudge physicians to order broader cognitive checks.
Vision‑friendly habits help, too. Good lighting, high‑contrast text, and blue‑green filters reduce strain and may delay functional loss.
Finally, keep blood vessels healthy. Controlling blood pressure, diabetes, and cholesterol supports both retinal and cerebral circulation, tying the two organs together.
The study is published in Scientific Reports.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–
Why we’ll have to wait a bit to say yay or nay on a 2024 YR4 lunar impact.
Predicting the precise path of a new asteroid or comet is a complex affair; the more observations you have, the better you know where an object will be, years hence.
Asteroid 2024 YR4 was discovered late last year, and found to have a trajectory passing through the Earth/Moon system in 2032. The world’s telescopes focused on the potential threat and downgraded the chance to negligible for the Earth…but the asteroid still has a non-zero chance of hitting the Moon. As the asteroid became too dim to continue observing, its Moon impact chance stood at 4%. When will we update this number? Not until it does another close flyby in 2028.
Asteroid 2024 YR4 was discovered by the Asteroid Terrestrial-impact Last Alert System (ATLAS) as a +13th magnitude object moving through the constellation Hydra the Sea Serpent on the night of December 27th, 2024. The 60-meter space rock was actually discovered two days after closest Earth approach, which was on Christmas Day at 828,800 kilometers away, just over twice the Earth-Moon distance.
As is the case with lots of asteroids approaching from the sunward direction, 2024 YR4 was outbound on discovery. The Chelyabinsk bolide that exploded over the Russian city of the same name on February 15th, 2013 snuck up on us as well… and just last week, a daytime fireball was seen over central Georgia, and showered an area with recovered fragments.
The asteroid immediately created a stir, as there seemed to be a slight chance of an Earth impact on December 22nd, 2032. At 60 meters across, the asteroid is smaller than an extinction triggering impact such as the 10 kilometer Chicxulub asteroid which hit off of the Yucatan peninsula 66 million years ago, and was instead dubbed a ‘city killer…’ Maps were even published showing a tentative impact swath across South America, the Atlantic, Africa and the Middle East.
Credit: A risk level comparison for dangerous asteroids. Credit: ESA.
It even briefly held a notable Torino scale rating of 3 during its first month of discovery—one of few new asteroid discoveries to do so. 99942 Apophis had the highest, briefly hitting a rating of 4 for its 2029 pass, after discovery in 2004. As is usually the case, further observations including ones tasked to JWST shrunk the potential for an Earth impact to zero. However, the chances of a lunar impact actually crept upward, and now stand at 4%.
More observations are needed before we’ll know for sure. Unfortunately, we’ll have to wait to refine the orbit of 2024 YR4 further. On a 4 year orbit around the Sun, the asteroid ranges from a perihelion 0.85 AU from the Sun, out to an aphelion in the asteroid belt at 4.18 AU distant. Next aphelion for the asteroid is set for November 22nd, 2026.
Bruno Crater; an impact from 2024 YR4 may produce a similar result. Credit: NASA/LRO
What if asteroid 2024 YR4 actually hit the Moon? The Moon phase at impact will be 70% illuminated, waning gibbous on December 22nd, 2032 around 15:20 Universal Time (UT), the approximate time that 2024 YR4 will be in the vicinity of the Moon. Viewing would favor the Pacific Ocean region… though it’s uncertain at this point just what area of the Moon the asteroid would strike, if it hits the Moon at all. Certainly, the near nighttime side would be favorable for observation. The asteroid will be approaching the Earth from the direction of Sagittarius (the same constellation the Sun crosses in late December).
An impression of a small asteroid striking the gibbous Moon. Credit: Created by the author using ChatGPT.
Clearly there’s lots more out there to discover in terms of near-Earth asteroids. Vera Rubin revealed an amazing 2,104 new asteroids on its first run. NASA still plans to launch their NEO Surveyor mission to scout for asteroids in September 2027. The mission survived the current budget FY2026 cuts and passed its Critical Design Review phase earlier this year.
The European Space Agency (ESA) also has plans to hunt for asteroids using space-based assets as well. ESA’s Near Earth Object Mission in the Infrared (NEOMIR) will head to the Sun-Earth L1 point. This location is the home of the Solar Heliospheric Observatory (SOHO), the Deep Space Climate Observatory (DSCOVR) and more. Launching in the 2030s, NEOMIR would use its infrared ‘eyes’ to scour the sky, detecting objects such as 2024 YR4 before they came close to the Earth.
NEOMIR in space. Credit: ESA
“We looked at how NEOMIR would have performed in this situation, and the simulations surprised even us,” says Richard Moissl (Head of ESA’s Defense Office) in a recent press release, referring to the expected performance of NEOMIR. “NEOMIR would have detected asteroid 2024 YR4 about a month earlier than ground-based telescopes did. This would have given astronomers more time to study the asteroid’s trajectory and allowed them to much sooner rule out any chance of Earth impact in 2032.”
A lunar impact would give astronomers a first-ever opportunity to witness such an event first-hand…and study such an event like never before. And heck, it would put on a show for amateur astronomers as well (assuming it doesn’t hit the lunar farside). Is it wrong that I kind of want to see this happen?
Over 33.3% of pregnancy-related deaths are due to cardiovascular diseases, with acute myocardial infarction (AMI) being a significant contributor to maternal mortality.1 While the risk of AMI during pregnancy and the early postpartum period is relatively low (6 to 10 cases per 100,000 pregnancies), it is three times higher compared to non-pregnant women of reproductive age.2,3 Pregnant women who experience AMI have a 22-fold higher in-hospital mortality risk, with a 37% mortality rate and the potential loss of both mother and child.1,4 In the past 20 years, the incidence of AMI in pregnancy has increased, likely due to the rising average maternal age and greater prevalence of risk factors.5,6 The etiology of AMI also differs significantly. In the general population, most cases result from atherosclerotic coronary artery disease. However, among pregnant women, approximately 40% of AMI cases are associated with spontaneous coronary artery dissection (SCAD). Atherosclerosis accounts for around 27% of cases, while myocardial infarction with non-obstructive coronary arteries (MINOCA) represents up to 29%.2,7,8
The pathophysiology of SCAD remains unclear and likely multifactorial. It involves spontaneous coronary artery dissection due to an intramural hematoma, with or without intimal rupture.7,8 SCAD is often linked to arteriopathies, connective tissue disorders, and autoimmune diseases.8 Pregnant women, especially in the third trimester and postpartum, are at higher risk, particularly those who have undergone infertility treatment, including in vitro fertilisation.9–11
A 28-year-old female, gravida 3, at 37 weeks of gestation, was admitted to the district central hospital via emergency medical services with complaints of a single episode of vomiting, nausea, constrictive retrosternal pain, and a sensation of rapid heartbeat. She attributed the onset of symptoms to the consumption of a low-alcohol beverage the previous evening (300 mL of light beer) along with potato chips.
Her medical history revealed a prior smoking habit, with a four-year history of tobacco use, smoking up to 15 cigarettes per day (pack-year index: 3). She discontinued smoking upon conception of the current pregnancy. Her family history was unremarkable for cardiovascular disease, connective tissue disorders, or sudden cardiac death. The patient’s obstetric history included a spontaneous miscarriage at 11 weeks of gestation in 2015. In 2018, she had an uncomplicated full-term pregnancy, resulting in a vaginal delivery of a healthy female neonate weighing 3300 g.
The emergency medical team administered antispasmodics with minimal effect. The time from the onset of symptoms to hospitalization was 7 hours. An electrocardiogram (ECG) was performed immediately upon arrival (Figure 1, ECG from 24.09.23), showing no signs of acute ischemia. Troponin I was measured at 0.10 ng/mL (normal value: up to 0.16 ng/mL). Routine laboratory tests showed elevated total cholesterol (TC) at 7.03 mmol/L, low-density lipoprotein cholesterol (LDL-C) at 4.70 mmol/L, high-density lipoprotein cholesterol (HDL-C) at 1.48 mmol/L, and triglycerides (TG) at 2.74 mmol/L. These findings were considered physiological for late pregnancy and not indicative of a primary lipid disorder.
Figure 1 Initial ECG recording taken on admission. No signs of acute ischemia are seen.
|
Upon admission, the patient continued to experience recurrent episodes of constricting retrosternal pain. A repeat investigation was performed, revealing a significant rise in troponin I levels, which was 14.31 ng/mL, 4 hours after hospitalization. The repeat ECG (Figure 2, ECG from 24.09.23) showed ST-segment elevation in leads I, aVL, and V4-V6, with reciprocal ST depression in leads II, III, aVF, and negative T-waves in leads I and aVL. Echocardiography demonstrated septal and anterior left ventricular wall hypokinesis with left ventricular ejection fraction of 50%. Given the patient’s clinical symptoms, ECG findings, and the increase in myocardial necrosis markers, along with input from relevant specialists, the decision was made to transfer the patient to a center capable of providing specialized care.
![]() |
Figure 2 Follow-up ECG displaying ST-segment elevation and reciprocal changes, indicating acute ischemic injury.
|
Thus, the patient was admitted to the intensive care unit of the maternity hospital for further observation and continuous cardio-respiratory monitoring. An ultrasound was immediately performed in the obstetrics department to assess the fetal condition. At the time of admission, the patient did not report any complaints, and the ECG showed no abnormalities. Considering the transient, rapidly evolving changes on the ECG, which were clearly associated with retrosternal pain, and the significant rise in myocardial necrosis markers over time, a presumed diagnosis of acute type 2 myocardial infarction was made.
A decision was reached to proceed with conservative management, and the patient was started on enoxaparin 0.4 mL twice daily subcutaneously and acetylsalicylic acid (ASA) 100 mg once daily. The following day, the patient again complained of severe retrosternal pain, which did not alleviate despite the administration of nitrates and required opioid analgesics. In response, an echocardiogram was immediately performed, revealing hypokinesis of the anterior segment of the left ventricular wall. The repeat ECG (Figure 3, ECG from 26.09.23) was registered. The aforementioned changes were interpreted as an expansion of AMI, prompting the decision to proceed with urgent coronary angiography to determine the subsequent treatment strategy. During the coronary angiography, a femoral access was used. A long dissection in the mid-distal segment of the left anterior descending artery (LAD) was noted (Figure 4A). Two Resolute Integrity (DES) stent systems were then implanted using the “stent-in-stent” technique. Follow-up angiography showed complete stent deployment in the LAD, with adequate positioning and restoration of the main blood flow through the LAD (TIMI – 3; TIMI myocardial perfusion grade – 3) (Figure 4B). No significant narrowings were identified in the left circumflex artery or the right coronary artery.
![]() |
Figure 3 ECG taken during symptom recurrence, revealing expansion of ischemic changes.
|
![]() |
Figure 4 (A) Coronary angiography identifying a long dissection in the left anterior descending artery (arrow). (B) Post-stenting angiography confirming restored blood flow in the affected artery (ellipse).
|
Following PCI, clopidogrel (75 mg once daily) and bisoprolol (1.25 mg once daily) were added to the patient’s treatment regimen. Regarding pregnancy management, multiple consultations were held with a multidisciplinary team comprising specialists in obstetrics and cardiology. The patient remained under continuous surveillance in the high-risk obstetric intensive care unit. Given the gestational age of 37–38 weeks and the elevated risk associated with surgical delivery, adjustments were made to the antiplatelet and anticoagulant therapy. Specifically, clopidogrel was discontinued, and enoxaparin was replaced with heparin. Heparin was administered at a dose of 7,000 IU every six hours, with activated partial thromboplastin time monitoring. It was recommended that the final dose be administered no later than four hours before the planned delivery.
At 39 weeks of gestation, due to the onset of spontaneous labor and rupture of membranes in the presence of a pure breech presentation, a decision was made to proceed with delivery via cesarean section. A female neonate was delivered, weighing 3,300 g and measuring 54 cm in length, with Apgar scores of 8/8. On postoperative day 4, the patient and her newborn were discharged home. Recommendations were provided regarding ongoing pharmacological therapy, specifically the continuation of DAPT (ASA and clopidogrel) for the next 12 months.
The subsequent follow-up period was uneventful. At 4 months postpartum, her lipid profile had normalized: total cholesterol 4.71 mmol/L, LDL-C 2.9 mmol/L, HDL-C 1.54 mmol/L, and triglycerides 0.93 mmol/L, supporting the interpretation that the earlier elevation was related to physiological gestational changes. One year after myocardial infarction, ECG revealed persistent scarring at the apex extending to the interventricular septum, mild ST-segment elevation, and biphasic T waves in leads V3–V4 (Figure 5, ECG from 11.11.2024). Echocardiography showed a preserved left ventricular ejection fraction. No clinical evidence of a vascular or systemic connective tissue disorder has been observed during the one-year follow-up to date.
![]() |
Figure 5 Follow-up ECG one year later, showing residual non-specific ST-T abnormalities.
|
Cardiovascular risk factors in pregnancy are consistent with those in the general population, including a family history of cardiovascular disease, dyslipidemia, diabetes, and smoking.12 Pregnancy-specific factors include polycystic ovary syndrome, early menarche, maternal age over 35, gestational diabetes, pre-eclampsia, and hormonal therapy use.13
Although the patient had ceased smoking during pregnancy, her prior tobacco use may have contributed to vascular vulnerability. Several studies have identified smoking as a potential risk factor for SCAD, both in pregnancy-associated and non-pregnancy cases, likely due to its role in vascular inflammation and endothelial dysfunction. In particular, a meta-analysis of women with SCAD, smoking was among the most frequently reported cardiovascular risk factors, present in nearly a quarter of cases.14 Another study found a significant association between smoking and increased mortality in SCAD patients.15
Similarly, while gestational hyperlipidemia has been proposed to influence vascular function through mechanisms such as endothelial dysfunction or oxidative stress, its direct role in SCAD remains unproven. SCAD is typically not associated with lipid deposition or coronary atherosclerotic plaque.16 During pregnancy, physiological hyperlipidemia is well recognized: total cholesterol and LDL-C typically rise by 30–50%, triglycerides by 50–100%, and HDL-C by 20–40% as gestation progresses.17 The patient’s third-trimester lipid profile was consistent with these expected changes, and normalization at follow-up supported the interpretation of a transient physiological response. These findings underscore the importance of interpreting lipid values in pregnancy within trimester-specific reference ranges, rather than assuming pathological significance in isolation.
Pregnancy-related SCAD likely results from increased shear stress, elevated progesterone reducing arterial elasticity, and estrogen-induced hypercoagulation and collagen inhibition. Increased cardiac output and blood volume further contribute. It often affects major coronary arteries, leading to reduced ejection fraction and severe maternal-fetal complications.18–23
Managing patients with pregnancy-related SCAD is challenging, particularly in diagnosing the condition. In 70% of cases, SCAD presents with typical ST-segment elevation on ECG.24 However, nearly one-third of patients show no ECG signs of coronary circulation impairment.10,25 In the presented clinical case, early ECG showed a transient ST elevation in the anterior-lateral wall, which resolved after pain relief, initially suggesting vasospastic angina. The key indicator of myocardial injury was the sustained rise in troponin I levels. Notably, troponin is preferred over CK-MB in pregnant women, as CK-MB can rise due to uterine contractions or cell breakdown during delivery, with lower specificity in pregnancy and postpartum.26
Given the absence of pronounced clinical symptoms at the time of our patient’s transfer, a conservative treatment approach was initially chosen. However, this was later reassessed due to the recurrence of symptoms (angina, vomiting), accompanied by deteriorating ECG changes and severe arrhythmias. There is no consensus on the preferred management strategy for pregnant women with AMI, and each case requires an individual approach. Conservative management of SCAD not related to pregnancy has shown better outcomes than in pregnant women and the early postpartum period.9,23,24 In pregnant women with SCAD, coronary interventions were associated with a higher risk of dissection progression and the occurrence of new iatrogenic dissections during the procedure.23–25 Additionally, concern arises over the potential impact of X-ray exposure on the fetus during coronary angiography (CAG). During CAG, the patient’s radiation dose is less than 20 mGy, while the fetal radiation dose is estimated at 0.074 mGy.27 The teratogenic risk to the fetus is minimal for doses below 50 mGy and potentially fatal for doses above 150 mGy, depending on gestational age.28 Therefore, it can be concluded that the radiation dose during coronary angiography is generally safe for most pregnant patients.29 An alternative option is the use of computed tomography coronary angiography, particularly in non-ST elevation myocardial infarction patients, but it may cause delays and is not always effective in detecting small areas of dissection.30 The access route for percutaneous intervention is also crucial. Radial access, as opposed to femoral access, reduces radiation exposure to the fetus, as it avoids direct X-ray exposure, making it more often recommended for pregnant women. Moreover, radial access is associated with a lower risk of complications, such as bleeding.31 However, some studies suggest that femoral access may be more effective for pregnant women with SCAD, as it has been linked to nearly three times fewer iatrogenic dissections compared to radial access.32,33 In our patient, femoral access was used, and no expansion of the dissection zone was observed during the procedure.
Pharmacological management, particularly dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), has specific considerations. According to the latest European Society of Cardiology guidelines, clopidogrel is recommended as part of DAPT in pregnant women post-PCI, as it is considered safer than glycoprotein IIb/IIIa inhibitors, due to a lack of data on their use in pregnancy.10 However, there are no clear guidelines on the duration of DAPT during labour for patients at high risk of thrombosis or those with recent intervention. Some studies show positive outcomes, while others report serious side effects from prolonged DAPT use.25 A decision was made to continue long-term DAPT, with a short-term discontinuation of clopidogrel before the planned cesarean section. After discharge, the patient continued DAPT for 12 months with no complications.
While the case highlights key aspects of diagnosis and management, it also has certain limitations. These are inherent to a single-patient observation. Intravascular ultrasound or optical coherence tomography was not performed, which might have provided more precise characterization of the arterial dissection. Additionally, no further investigations were undertaken to evaluate possible underlying vascular or connective tissue disorders. However, the case reflects real-world clinical complexity, where decisions must often be made based on evolving symptoms and limited diagnostic data.
The issue of myocardial infarction during pregnancy involves several aspects, including challenges in emergency diagnosis due to a low index of suspicion among young women without traditional risk factors, as well as the absence of clear, definitive algorithms for selecting a management strategy (conservative/invasive). Additionally, there is uncertainty regarding the volume and duration of anticoagulant and antiplatelet therapy. Since the likelihood of conducting randomized clinical trials among pregnant women is quite limited and problematic, the accumulation of sufficient clinical case reports from real-world practice will, in the future, allow for the formulation of a well-founded expert opinion and evidence-based recommendations for managing this patient cohort.
This is a case report without statistical analysis of the raw medical record data. All medical data involving the patient were documented in the patient’s medical records. If necessary, more detailed imaging data or laboratory data can be provided by the corresponding author upon reasonable request.
Ethical review and approval were not required for the study involving human participants in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this report.
The patient agreed to publish her medical data including imaging data and laboratory data, and signed the informed consent.
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
This study was not supported by any external funds.
All the authors declare that they have no conflicts of interest in this medical case report and have not received any financial support.
1. Markson F, Shamaki RG, Antia A, Osabutey A, Ogunniyi MO. Trends in the incidence and in-patient outcomes of acute myocardial infarction in pregnancy: insights from the national inpatient sample. Am Heart J Plus. 2023;34:100318. doi:10.1016/j.ahjo.2023.100318
2. Smilowitz NR, Gupta N, Guo Y, et al. Acute myocardial infarction during pregnancy and the puerperium in the United States. Mayo Clin Proc. 2018;93(10):1404–1414. doi:10.1016/j.mayocp.2018.04.019
3. James AH, Jamison MG, Biswas MS, Brancazio LR, Swamy GK, Myers ER. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation. 2006;113(12):1564–1571. doi:10.1161/CIRCULATIONAHA.105.576751
4. Burlingame J, Horiuchi B, Ohana P, Onaka A, Sauvage LM. The contribution of heart disease to pregnancy-related mortality according to the pregnancy mortality surveillance system. J Perinatol. 2012;32(3):163–169. doi:10.1038/jp.2011.74
5. Balgobin CA, Zhang X, Lima FV, et al. Risk factors and timing of acute myocardial infarction associated with pregnancy: insights from the national inpatient sample. J Am Heart Assoc. 2020;9(21):e016623. doi:10.1161/JAHA.120.016623
6. Gédéon T, Akl E, D’Souza R, et al. Acute myocardial infarction in pregnancy. Curr Probl Cardiol. 2022;47(11):101327. doi:10.1016/j.cpcardiol.2022.101327
7. Elkayam U, Jalnapurkar S, Barakkat MN, et al. Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. Circulation. 2014;129(16):1695–1702. doi:10.1161/CIRCULATIONAHA.113.002054
8. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC scientific document group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–3241. doi:10.1093/eurheartj/ehy340
9. Saw J, Humphries K, Aymong E, et al. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol. 2017;70(9):1148–1158. doi:10.1016/j.jacc.2017.06.053
10. Lebrun S, Bond RM. Spontaneous coronary artery dissection (SCAD): the underdiagnosed cardiac condition that plagues women. Trends Cardiovasc Med. 2018;28(5):340–345. doi:10.1016/j.tcm.2017.12.004
11. Zeven K. Pregnancy-associated spontaneous coronary artery dissection in women: a literature review. Curr Ther Res. 2023;98:100697. doi:10.1016/j.curtheres.2023.100697
12. Kealey A. Coronary artery disease and myocardial infarction in pregnancy: a review of epidemiology, diagnosis, and medical and surgical management. Can J Cardiol. 2010;26(6):185–189. doi:10.1016/s0828-282x(10)70397-4
13. Nguyen AH, Murrin E, Moyo A, et al. Ischemic heart disease in pregnancy: a practical approach to management. Am J Obstet Gynecol MFM. 2024;6(3):101295. doi:10.1016/j.ajogmf.2024.101295
14. Apostolović S, Ignjatović A, Stanojević D, et al. Spontaneous coronary artery dissection in women in the generative period: clinical characteristics, treatment, and outcome-a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1277604. doi:10.3389/fcvm.2024.1277604
15. Adams C, He M, Hughes I, Singh K. Mortality in spontaneous coronary artery dissection: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2021;98(7):1211–1220. doi:10.1002/ccd.29488
16. Stanojevic D, Apostolovic S, Kostic T, et al. A review of the risk and precipitating factors for spontaneous coronary artery dissection. Front Cardiovasc Med. 2023;10:1273301. doi:10.3389/fcvm.2023.1273301
17. Mulder JWCM, Kusters DM, Roeters van Lennep JE, Hutten BA. Lipid metabolism during pregnancy: consequences for mother and child. Curr Opin Lipidol. 2024;35(3):133–140. doi:10.1097/MOL.0000000000000927
18. Maas AHEM, Bouatia-Naji N, Persu A, Adlam D. Spontaneous coronary artery dissections and fibromuscular dysplasia: current insights on pathophysiology, sex and gender. Int J Cardiol. 2019;286:220–225. doi:10.1016/j.ijcard.2018.11.023
19. Yip A, Saw J. Spontaneous coronary artery dissection – a review. Cardiovasc Diagn Ther. 2015;5(1):37–48. doi:10.3978/j.issn.2223-3652.2015.01.08
20. Giacoppo D, Capodanno D, Dangas G, Tamburino C. Spontaneous coronary artery dissection. Int J Cardiol. 2014;175(1):8–20. doi:10.1016/j.ijcard.2014.04.178
21. Vijayaraghavan R, Verma S, Gupta N, Saw J. Pregnancy-related spontaneous coronary artery dissection. Circulation. 2014;130(21):1915–1920. doi:10.1161/CIRCULATIONAHA.114.011422
22. Abbott JD, Curtis JP, Murad K, et al. Spontaneous coronary artery dissection in a woman receiving 5-fluorouracil: a case report. Angiology. 2003;54(6):721–724. doi:10.1177/000331970305400613
23. Havakuk O, Goland S, Mehra A, Elkayam U. Pregnancy and the risk of spontaneous coronary artery dissection: an analysis of 120 contemporary cases. Circ Cardiovasc Interv. 2017;10(3):e004941. doi:10.1161/CIRCINTERVENTIONS.117.004941
24. Tweet MS, Hayes SN, Codsi E, Gulati R, Rose CH, Best PJM. Spontaneous coronary artery dissection associated with pregnancy. J Am Coll Cardiol. 2017;70(4):426–435. doi:10.1016/j.jacc.2017.05.055
25. Lindor RA, Tweet MS, Goyal KA, et al. Emergency department presentation of patients with spontaneous coronary artery dissection. J Emerg Med. 2017;52(3):286–291. doi:10.1016/j.jemermed.2016.09.005
26. Siromakha SO, Arvanytakvy SS, Rudenko SA, Lazorishenetc VV. Coronary insufficiency during pregnancy. Epidemiology, methods of diagnosis and treatment. Ukr J Perinatol Pediatr. 2019;3:32–39. doi:10.15574/PP.2019.79.32
27. Colletti PM, Lee KH, Elkayam U. Cardiovascular imaging of the pregnant patient. Am J Roentgenol. 2013;200(3):515–521. doi:10.2214/AJR.12.9864
28. Kuba K, Wolfe D, Schoenfeld AH, Bortnick AE. Percutaneous coronary intervention in pregnancy: modeling of the fetal absorbed dose. Case Rep Obstet Gynecol. 2019;2019:8410203. doi:10.1155/2019/8410203
29. Alameh A, Jabri A, Aleyadeh W, et al. Pregnancy-associated myocardial infarction: a review of current practices and guidelines. Curr Cardiol Rep. 2021;23:142. doi:10.1007/s11886-021-01579-z
30. Joshi FR. CT rather than invasive angiography for pregnant patients with NSTEMI?: More delay and more radiation. J Am Coll Cardiol. 2016;68(24):2716–2717. doi:10.1016/j.jacc.2016.08.075
31. Prokšelj K, Brida M. Cardiovascular imaging in pregnancy. Int J Cardiol Congenit Heart Dis. 2021;5(Suppl. 1):100235. doi:10.1016/j.ijcchd.2021.100235
32. Prakash R, Starovoytov A, Heydari M, Mancini GB, Saw J. Catheter-induced iatrogenic coronary artery dissection in patients with spontaneous coronary artery dissection. JACC: Cardiovasc Interv. 2016;9(17):1851–1853. doi:10.1016/j.jcin.2016.06.026
33. Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American heart association. Circulation. 2018;137(19):e523–e557. doi:10.1161/CIR.0000000000000564